Barriers in access to oncology drugs – a global crisis
Carlos Barrios, Gilberto de Lima Lopes, Mastura Md Yusof, Fidel Rubagumya, Piotr Rutkowski, Manju Sengar DOI: 10.1038/s41571-022-00700-7 Full link: https://www.nature.com/articles/s41571-022-00700-7
Oral Lichen Planus and Oral Squamous Cell Carcinoma share key oncogenic signatures
Cristóvão Antunes de Lanna, Beatriz Nascimento Monteiro da Silva, Andreia Cristina de Melo, Martín H Bonamino, Lísia Daltro Borges Alves, Luis Felipe Ribeiro Pinto, Abel Silveira Cardoso, Héliton Spíndola Antunes, Mariana Boroni, Daniel Cohen Goldemberg DOI: 10.1038/s41598-022-24801-6 Full link: https://www.nature.com/articles/s41598-022-24801-6
Clinical implication of low estrogen receptor (ER-low) expression in breast cancer
Tomás Reinert, Fanny Cascelli, Cristiano Augusto Andrade de Resende, Aline Coelho Gonçalves, Vania Sanchez Prette Godo, Carlos Henrique Barrios DOI: 10.3389/fendo.2022.1015388 Full link: https://www.frontiersin.org/articles/10.3389/fendo.2022.1015388/full
Innovation in Breast Cancer Symposium – Lisbon Edition
The Innovation in Breast Cancer Symposium, will be held in online format on February 17th and 18th, 2022. The two-day international scientific program aims to provide state-of-the-art information on breast cancer, achieving a balance of clinical, translational, and basic research, as well as providing a forum for interaction, communication, and interdisciplinary education for specialists with a special interest in breast cancer. The registration period is now open. You can find all the information on the website through which you will have access to the registration section, general information, etc. Learn more: www.innovationinbreastcancer.com/lisbon/
Radiotherapy activity in the Covid-19 pandemic: Brazil´s operational national-level study
Fabio Y. Moraes, Andre G. Gouveia , Renato P. Lima, Gustavo A. Viani, Vanessa F. Brassati, Ana C. Hamamura DOI: 10.1016/j.jcpo.2022.100367 Full link: https://www.sciencedirect.com/science/article/pii/S2213538322000467
Looking beyond carboplatin and paclitaxel for the treatment of advanced/recurrent endometrial cancer
Maria Rubinstein, Sherry Shen, Bradley J Monk, David S P Tan, Angélica Nogueira-Rodrigues, Daisuke Aoki, Jalid Sehouli, Vicky Makker DOI: 10.1016/j.ygyno.2022.10.012 Full link: https://linkinghub.elsevier.com/retrieve/pii/S0090825822018893
Moderately hypofractionated radiation therapy for breast cancer: A Brazilian cohort study
Gabriela S M de Siqueira , Samir A Hanna , Larissa F de Moura , Fabiana Accioli Miranda , Heloísa de Andrade Carvalho, Gustavo Nader Marta DOI: 10.1016/j.lana.2022.100323 Full link: https://www.sciencedirect.com/science/article/pii/S2667193X22001405?via%3Dihub
In reply to Li et al. Letter to the editor. “Once daily (OD) versus twice-daily (BID) chemoradiation for limited stage small cell lung cancer (LS-SCLC): A meta-analysis of randomized clinical trials.”
Gustavo A. Viani, Andre G. Gouveia, Fabio Y. Moraes DOI: 10.1016/j.radonc.2022.09.017 Full link: https://doi.org/10.1016/j.radonc.2022.09.017
Radiotherapy activity in the COVID 19 pandemic: Brazil’s operational national-level study
Fabio Y Moraes, Andre G Gouveia, Renato P Lima, Vanessa F Bratti, Ana C Hamamura, Gustavo A Viani DOI: 10.1016/j.jcpo.2022.100367 Full link: https://pubmed.ncbi.nlm.nih.gov/36216270/
Radiotherapy activity in the COVID 19 pandemic: Brazil’s operational national-level study
Fabio Y Moraes, Andre G Gouveia, Renato P Lima, Vanessa F Bratti, Ana C Hamamura, Gustavo A Viani DOI: 10.1016/j.jcpo.2022.100367 Full link: https://pubmed.ncbi.nlm.nih.gov/36216270/